Cerebrospinal fluid markers in dementia with Lewy bodies compared with Alzheimer disease

Archives of Neurology

Volumn 60, Issue 9, 2003, Pages 1218-1222

  Gómez Tortosa, Estrella ^a,b   Gonzalo, Isabel ^b   Fanjul, Samira ^a   Sainz, Maria José ^a   Cantarero, Susana ^a   Cemillán, Carlos ^c   García Yébenes, Justo ^a,b   Del Ser, Teodoro ^c  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c HOSPITAL SEVERO OCHOA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; INTERLEUKIN 1BETA; INTERLEUKIN 6; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMENTIA; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LEWY BODY; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PARKINSONISM; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ASTROCYTES; COGNITION DISORDERS; CUES; FEMALE; HUMANS; INTERLEUKIN-1; INTERLEUKIN-6; LEWY BODY DISEASE; MALE; MICROGLIA; NEUROFIBRILLARY TANGLES; NEUROPSYCHOLOGICAL TESTS; TAU PROTEINS;

EID: 0042421736     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.60.9.1218     Document Type: Article

References (22)

1. Dickson D, Crystal H, Mattiace L. Diffuse Lewy body disease: light and electron microscopic immunocytochemistry of senile plaques. Acta Neuropathol (Berl). 1989;78:572-584.
2. Hansen L, Masliah E, Galasko D, Terry R. Plaque-only Alzheimer disease is usually the Lewy body variant and vice versa. J Neuropathol Exp Neurol. 1993;52:648-654.
3. Shepherd CE, Thiel E, McCann H, Harding AJ, Halliday GM. Cortical inflammation in Alzheimer's disease but not in dementia with Lewy bodies. Arch Neurol. 2000;57:817-822.
4. Rozemuller AJ, Eikelenboom P, Theeuwes JW, Jansen Steur EN, de Vos RA. Activated microglial cells and complement factors are unrelated to cortical Lewy bodies. Acta Neuropathol (Berl). 2000;100:701-708.
5. Szpak GM, Lechowicz W, Lewandowska E, et al. Neurons and microglia in central nervous system immune response to degenerative processes, part 1: Alzheimer's disease and Lewy body variant of Alzheimer's disease: quantitative study. Folia Neuropathol 2001;39:181-192.
6. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
7. McKeith IG, Galasko D, Kosaka K, et al, for the Consortium on Dementia with Lewy bodies. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996;47:1113-1124.
8. Andreasen N, Minthon L, Davidsson P, et al. Evaluation of CSF tau and CSF-Aβ42 as diagnostic markers for AD in clinical practice. Arch Neurol. 2001;58: 373-379.
9. Tapiola T, Overmyer M, Lehtovirta M, et al. The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer's disease. Neuroreport. 1997;8:3961-3963.
10. Gómez-Tortosa E, Newell K, Irizarry MC, Albert M, Growdon JH, Hyman BT. Clinical and quantitative pathologic correlates of dementia with Lewy bodies. Neurology, 1999;53:1284-1291.
11. del Ser T, Hachinski V, Merskey H, Munoz DG. Clinical and pathologic features of two groups of patients with dementia with Lewy bodies: effect of coexisting Alzheimer-type lesion load. Alzheimer Dis Assoc Disord. 2001;15:31-44.
12. McKeith IG, Ballard CG, Perry RH, et al. Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology, 2000;54:1050-1058.
13. Andreasen N, Hesse C, Davidsson P, et al. Cerebrospinal fluid β-amyloid (1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol, 1999;56: 673-680.
14. Samuels SC, Silverman JM, Marin DB, et al. CSF β-amyloid, cognition, and APOE genotype in Alzheimer's disease. Neurology, 1999;52:547-551.
15. Riemenschneider M, Schmolke M, Lautenschlager N, et al. Cerebrospinal β-amyloid (1-42) in early Alzheimer's disease: association with apolipoprotein E genotype and cognitive decline. Neurosci Lett. 2000;284:85-88.
16. Kanemaru K, Kameda N, Yamanouchi H. Decreased CSF amyloid β42 and normal tau levels in dementia with Lewy bodies. Neurology. 2000;54:1875-1876.
17. Parnetti L, Lanari A, Amici S, Gallai V, Vanmechelen E, Hulstaert F, for the Phospho-Tau International Study Group. CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Neurol Sci. 2001;22:77-78.
18. Buerger K, Zinkowski R, Teipel S, et al. Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol. 2002;59:1267-1272.
19. Van Everbroeck B, Dewulf E, Pals P, Lübke U, Martin JJ, Cras P. The role of cytokines, astrocytes, microglia and apoptosis in Creutzfeldt-Jakob disease. Neurobiol Aging. 2002;23:59-64.
20. Martinez M, Fernández-Vivancos E, Frank A, De la Fuente M, Hernanz A. Increased cerebrospinal fluid fas (Apo-1) levels in Alzheimer's disease: relationship with IL-6 concentrations. Brain Res. 2000;869:216-219.
21. Jellinger KA, Rösler N, Wichart I. Cerebrospinal fluid interleukin-6 levels: a possible marker of disease activity [letter]. Ann Neurol. 2001;50:828.
22. Rösler N, Wichart I, Jellinger KA. Intra vitam lumbar and post mortem ventricular cerebrospinal fluid immunoreactive interleukine-6 in Alzheimer's disease patients. Acta Neurol Scand. 2001;103:126-130.